Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Novartis
Mayo Clinic
Indiana University
ARCAGY/ GINECO GROUP
Novartis
Yonsei University
Grupo Espanol de Investigacion en Sarcomas
Emerald Clinical Inc.
Fox Chase Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Northwestern University
Cancer Trials Ireland
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
University Hospital Muenster
University of Virginia
Novartis
Washington University School of Medicine
Grupo Espanol de Investigacion en Sarcomas
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
University of California, San Francisco
Lumos Pharma
Medical University of South Carolina
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNICANCER
UNICANCER
Kidney Cancer Research Bureau
Centre Leon Berard
National Cancer Institute (NCI)
University of California, Irvine
National Cancer Institute (NCI)
Grupo Espanol de Tumores Neuroendocrinos
Dana-Farber Cancer Institute
Charite University, Berlin, Germany
Central European Society for Anticancer Drug Research
University of Utah
National Cancer Institute (NCI)
University of Zurich
GlaxoSmithKline
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute, Naples
Hannover Medical School